LINC02326

Across TCGA pan-cancer cohorts, LINC02326 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC02326’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC02326 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02326 is over-expressed in tumor, although a few such as STAD show the opposite, repressed pattern.

PRAD and STAD are the cancer types where LINC02326 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02326 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.382	.001	2	view →
STAD	Female	III,IV	−0.229	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

LINC02326–PRAD

Open the PRAD breakdown →